Gastrointestinal Motility Disorder Clinical Trial
Official title:
Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water
To visualize the localization and to measure the volume of water in the small intestine by
T2-weighted MRI imaging after oral administration of 240 ml water (non-caloric water) and
after administration of 240 ml water containing 25.5 g sucrose (105 kcal, caloric water).
To measure pharmacokinetics of the probe-drugs paracetamol, talinolol and amoxicillin after
oral administration dissolved in 240 ml non-caloric and in 240 ml caloric water.
After swallowing, a drug first is deposited in the stomach together with the co-swallowed
water. However, the stomach is not the major place of drug absorption. Therefore, the
kinetics of gastric emptying plays a crucial role for the absorption process. In case of
dissolved or finely suspended drug particles, gastric emptying of the drugs occurs together
with gastric contents. The emptied liquid enters the small intestine where it is absorbed.
Under fasting conditions, the emptied phase consists of the water that was co-swallowed with
the drug (in clinical studies typically 240 ml) together with a small volume of gastric
juice. Under fed conditions, the emptied liquid phase is a caloric suspension. It is known
that both the gastric emptying and the intestinal absorption of pure water are rapid leading
usually to rapid absorption of water soluble drugs that are taken under fasting conditions.
In the contrary, delayed absorption under postprandial conditions is typically related to
delayed gastric emptying. However, velocity and extent of intestinal filling and the
absorption rate of the liquid phase from gut lumen are unknown.
Therefore, it is the primary objective of the study to determine the gastric emptying
kinetics of 240 ml water (non-caloric water) and of 240 ml water containing 25.5 g sucrose
(105 kcal, caloric water), the respective intestinal filling and the absorption rate of the
intestinal liquid using water sensitive magnetic resonance imaging (MRI).
To evaluate the functional meaning of gastric emptying, intestinal filling and water uptake
for oral drug absorption which are swallowed with non-caloric and caloric water,
pharmacokinetics of paracetamol, talinolol and amoxicillin will be studied after
administration with 240 ml non-caloric and 240 ml caloric water, respectively.
Paracetamol (acetaminophen) was chosen, because it is rapidly and completely absorbed from
all parts of the gut. The time of its appearance in blood is expected to be a surrogate for
the rate of gastric emptying. It is hypothesized that caloric content of the water for
administration does not influence the extent of paracetamol absorption.
Talinolol represents a well established probe drug for the intestinal efflux transport
protein ABCB1. Because expression of ABCB1 increases along the small intestine
(duodenum<jejunum<ileum), we hypothesize, that administration of talinolol with caloric
water leads to lower bioavailability and increase of the fecal excretion of the drug.
Amoxicillin acts as a probe drug for intestinal drug uptake via the dipeptide transporter
PEPT1 which is predominately expressed in proximal parts of the small intestine
((duodenum>jejunum>ileum). Because of this region-specific expression, we hypothesize, that
administration of amoxicillin with caloric water is associated with lower bioavailability.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Completed |
NCT01644240 -
A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Terminated |
NCT02573519 -
Gastrointestinal Motility Among Diabetes Patients
|
N/A | |
Recruiting |
NCT04764019 -
Intestinal Dysmotility in Patients With Functional Digestive Symptoms
|
N/A | |
Completed |
NCT03012594 -
Lanreotide in the Treatment of Small Bowel Motility Disorders
|
Phase 2 | |
Not yet recruiting |
NCT05268328 -
The Effect of Foot Reflexology After Cesarean Section
|
||
Completed |
NCT02245165 -
Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades
|
Phase 1 | |
Completed |
NCT03552510 -
Oropharyngeal Administration of Mother's Milk in Preterm Infants and Gastrointestinal Motility
|
N/A | |
Completed |
NCT01394055 -
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
|
Phase 1 | |
Active, not recruiting |
NCT00793195 -
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
|
Phase 2 | |
Recruiting |
NCT04208828 -
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
|
||
Active, not recruiting |
NCT06347367 -
Short-term Effect of Exercise and Self-manual Approaches to Bloating - Distention
|
N/A | |
Recruiting |
NCT05989763 -
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
|
N/A | |
Recruiting |
NCT04988438 -
Gastrointestinal Motor Disorders (Esophageal and Anorectal) After COVID-19
|